Q1 FY2026 core revenue grew 10.2% YoY (flat at CER), with strong performance from new launches and core brands offsetting mature portfolio declines. Investments in transformative medicines and R&D continue, with full-year guidance reaffirmed and a focus on deleveraging and dividend growth.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.